Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)
…, E Fertl, A Gass, K Gehring, C Gobbi… - Therapeutic …, 2021 - journals.sagepub.com
Multiple sclerosis is a complex, autoimmune-mediated disease of the central nervous system
characterized by inflammatory demyelination and axonal/neuronal damage. The approval …
characterized by inflammatory demyelination and axonal/neuronal damage. The approval …
[HTML][HTML] Acute coronary syndromes and Covid-19: exploring the uncertainties
Since an association between myocardial infarction (MI) and respiratory infections has been
described for influenza viruses and other respiratory viral agents, understanding possible …
described for influenza viruses and other respiratory viral agents, understanding possible …
Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis
…, L Kappos, G Disanto, C Zecca, C Gobbi… - Annals of …, 2017 - Wiley Online Library
… After 3 washes, the conjugated beads were suspended and stored at 4C. Biotinylated
mAB 2:1 was obtained from UmanDiagnostics and stored at 4C pending analysis. …
mAB 2:1 was obtained from UmanDiagnostics and stored at 4C pending analysis. …
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
…, S Galgani, GP Garmany, K Gehring, J Gitt, C Gobbi… - The Lancet, 2018 - thelancet.com
Background No treatment has consistently shown efficacy in slowing disability progression
in patients with secondary progressive multiple sclerosis (SPMS). We assessed the effect of …
in patients with secondary progressive multiple sclerosis (SPMS). We assessed the effect of …
Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis
…, C Tsagkas, M Amann, Y Naegelin, D Leppert, C Gobbi… - Brain, 2018 - academic.oup.com
Neuro-axonal injury is a key factor in the development of permanent disability in multiple
sclerosis. Neurofilament light chain in peripheral blood has recently emerged as a biofluid …
sclerosis. Neurofilament light chain in peripheral blood has recently emerged as a biofluid …
Association between tumor necrosis factor inhibitors and the risk of hospitalization or death among patients with immune-mediated inflammatory disease and COVID …
Importance Although tumor necrosis factor (TNF) inhibitors are widely prescribed globally
because of their ability to ameliorate shared immune pathways across immune-mediated …
because of their ability to ameliorate shared immune pathways across immune-mediated …
[HTML][HTML] A Review on the Current State and Future Perspectives of [99mTc]Tc-Housed PSMA-i in Prostate Cancer
…, D Carpanese, C Gobbi, L Melendez-Alafort, C Bolzati - Molecules, 2022 - mdpi.com
Recently, prostate-specific membrane antigen (PSMA) has gained momentum in tumor
nuclear molecular imaging as an excellent target for both the diagnosis and therapy of prostate …
nuclear molecular imaging as an excellent target for both the diagnosis and therapy of prostate …
Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study
…, I Kockum, K Blennow, H Zetterberg, C Gobbi… - The Lancet …, 2022 - thelancet.com
Background Serum neurofilament light chain (sNfL) is a biomarker of neuronal damage that
is used not only to monitor disease activity and response to drugs and to prognosticate …
is used not only to monitor disease activity and response to drugs and to prognosticate …
Association of disease-modifying treatment and anti-CD20 infusion timing with humoral response to 2 SARS-CoV-2 vaccines in patients with multiple sclerosis
…, G Martinetti, F Keller, C Gobbi, C Zecca - JAMA …, 2021 - jamanetwork.com
… Dr Gobbi received research grants or honoraria for speaking and consulting fees from
Almirall, Biogen, Celgene, Merck, Novartis, Roche, Sanofi Genzyme, Teva Pharma. Dr Zecca …
Almirall, Biogen, Celgene, Merck, Novartis, Roche, Sanofi Genzyme, Teva Pharma. Dr Zecca …
Association of brain atrophy with disease progression independent of relapse activity in patients with relapsing multiple sclerosis
…, A Chan, A Salmen, C Pot, C Bridel, C Zecca… - JAMA …, 2022 - jamanetwork.com
Importance The mechanisms driving neurodegeneration and brain atrophy in relapsing
multiple sclerosis (RMS) are not completely understood. Objective To determine whether …
multiple sclerosis (RMS) are not completely understood. Objective To determine whether …